This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Screening for MEN-II and von Hippel-Lindau syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Every patient with a phaeochromocytoma should be screened for both MEN-II and von Hippel-Lindau syndrome (VHS).

Screening is important because:

  • up to a quarter of patients will have either von Hippel Lindau or MEN type 2
  • it allows identification of life-threatening problems:
    • VHS - haemangioma of the brain and renal cancer
    • MEN-II - medullary carcinoma of the thyroid
  • of associated morbidity e.g. retinal angiomas can cause loss of vision in VHS
  • it allows subsequent screening of first-degree relatives

Screening should entail:

  • pentagastrium test - measure of calcitonin
  • measurement of serum parathyroid hormone
  • ophthalmoscopy - retinal angiomas
  • MRI of the brain - haemangioblastomas
  • CT of the kidneys and pancreas - retinal cysts and pancreatic cysts
  • ultrasonography of the testes - epididymal cystadenoma

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.